Sublinguale immunotherapie bij kinderen met allergische rinitis in de huisartsenpraktijk*

Cindy M.A. de Bot, Heleen Moed, Marjolein Y. Berger, Esther Röder, Wim C.J. Hop, Hans de Groot, Johan C. de Jongste, Roy Gerth van Wijk, Patrick J.E. Bindels en Johannes (Hans) C. van der Wouden

Sublingual immunotherapy in children allergic rhinitis in general practice


To investigate whether sublingual immunotherapy (SLIT) in children and adolescents with house mite-induced allergic rhinitis is effective and safe.


Randomised, double-blind, placebo-controlled trial.


Children aged 6-18 years (n = 251) recruited in primary care with a house dust mite-induced allergic rhinitis received either SLIT or placebo for 2 years. Symptoms, medication use and adverse events were assessed throughout the study. The primary outcome parameter was the mean total nose symptom score (scales 0-12) during the fall after a 2-year treatment.


The mean nose symptom score after 2 years of treatment showed no difference between SLIT and placebo. The mean score in the SLIT group was 2.26 (SD: 1.84) versus 2.02 in the placebo group (SD: 1.67; p = 0.08). There were no statistically significant differences in secondary outcome measures, or in subgroup analyses. The number of reported adverse events was comparable between both groups.


Sublingual immunotherapy with the house-dust mite allergen was not more effective than placebo in children with allergic rhinitis in primary care. The treatment is considered to be safe.

Conflict of interest/financial support: this study was sponsored by Artu Biologicals.